News | Radiation Therapy | February 03, 2016

Radioactive Medicine Markets Poised for Double-digit Growth

Nuclear medicine, proton therapy and brachytherapy expected to grow more than twice as fast as total global health expenditures to 2030

MEDraysintell, nuclear medicine, proton therapy, brachytherapy, global markets, 2030

February 3, 2016 — The nuclear medicine, proton therapy and brachytherapy markets represent less than 0.1 percent of global health expenditures but are expected to grow more than twice as fast, according to a new report from MEDraysintell.

Global health expenditures reached some $7.4 billion in 2014 and should grow by 3-4 percent per year to 2030. The nuclear medicine, proton therapy and brachytherapy markets reached about $5.8 billion in 2014 and are expected to grow by 10-11 percent annually to 2030. There is an increasing interest from investors and industry as new technologies and products are being marketed or under development.

The global nuclear medicine market is expected to reach $24 billion by 2030, showing an annual average growth of 11 percent, with radiotherapeutics being key drivers of this growth. The number of operational medical cyclotrons is also expected to grow with the emergence of the Asian and South American markets and the need of tools for new proprietary tracers.

The global proton therapy market saw record sales orders at just over $1 billion in 2015, more than twice as much as in 2014.

The global market for brachytherapy is expected to grow by 8 percent a year to 2030, mainly driven by microspheres and electronic brachytherapy and with the low-dose rate (LDR) brachytherapy seeds market mainly growing in emerging regions.

For more information:

Related Content

Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
AHRA and Canon Medical Systems Announce 2017 Putting Patients First Grant Winners
News | Patient Engagement | February 14, 2018
The Association for Medical Imaging Management (AHRA) and Canon Medical Systems recently announced the tenth annual...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
Overlay Init